


Innovative Polymer Lipid Particle (PoLiPa) technology



Accelerates G-Protein Coupled Receptor (GPCR) drug discovery

Domainex has established a generic platform to generate any purified GPCR without the need for thermostabilising mutations or detergents. This was achieved using Polymer Lipid Particle (PoLiPa)

technology that can stabilise GPCRs, by encapsulating the target protein in a polymer that encloses a small disc of the native cell membrane lipids.




Advantages of soluble PoLiPa-GPCRs

Enables rapid and generic access to pure samples of GPCRs.

- ⊘ Mutagenesis
- ⊘ Detergent
- ⊘ Refolding

PoLiPa-GPCRs are **pharmacologically intact** and **very stable** as they contain a disc of functionally important phospholipids. As such they can be used across multiple techniques and enable access to solution-based drug discovery methods.

Generation of PoLiPa-GPCRs at Domainex



Applications

FBDD

SBDD

Biophysical characterisation

Structural determination

DNA-encoded library screening

Biologic hit ID

Orphan receptor profiling

Development of this methodology was in collaboration with Prof. Tim Dafforn and with funding from the Innovate UK Biocatalyst Award.